Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones (Q59349171)

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Oncolytic Virotherapy: A Contest between Apples and Oranges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Oncolytic viruses: a new class of immunotherapy drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Oncolytic viruses: adenoviruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Applications of coxsackievirus A21 in oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Oncolytic Herpes Simplex Viral Therapy: A Stride toward Selective Targeting of Cancer Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Oncolytic Maraba Virus MG1 as a Treatment for Sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Identification of genetically modified Maraba virus as an oncolytic rhabdovirus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Measles to the Rescue: A Review of Oncolytic Measles Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Potential and clinical translation of oncolytic measles viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Recombinant Poxvirus and the Tumor Microenvironment: Oncolysis, Immune Regulation and Immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil".

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

The oncolytic poxvirus JX-863 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Targeting polysialic acid-abundant cancers using oncolytic adenoviruses with fibers fused to active bacteriophage borne endosialidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Mutational heterogeneity in cancer and the search for new cancer-associated genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Hallmarks of Cancer: The Next Generation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Designing and building oncolytic viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Oncolytic viruses as immunotherapy: progress and remaining challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Oncolytic virus-induced cell death and immunity: a match made in heaven?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

First-in-class small molecule potentiators of cancer virotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Dimethyl fumarate potentiates oncolytic virotherapy through NF-κB inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

RIP1 is a central signaling protein in regulation of TNF-α/TRAIL mediated apoptosis and necroptosis during Newcastle disease virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Tumor Restrictions to Oncolytic Virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Faster replication and higher expression levels of viral glycoproteins give the vesicular stomatitis virus/measles virus hybrid VSV-FH a growth advantage over measles virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 with nab-Paclitaxel Plus Gemcitabine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

NK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Synergistic interaction between oncolytic viruses augments tumor killing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Bacterial-mediated knockdown of tumor resistance to an oncolytic virus enhances therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Brief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Live-attenuated bacteria as a cancer vaccine vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Salmonella Vaccines: Conduits for Protective Antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Prospects for combined use of oncolytic viruses and CAR T-cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

The blockade of immune checkpoints in cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Immune checkpoint inhibitors: new strategies to checkmate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

A Recombinant Antibody-Expressing Influenza Virus Delays Tumor Growth in a Mouse Model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Arming oncolytic viruses to leverage antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Oncolytic vesicular stomatitis virus expressing interferon-γ has enhanced therapeutic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Can immunostimulatory agents enhance the abscopal effect of radiotherapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Oncolytic vaccinia virus in combination with radiation shows synergistic antitumor efficacy in pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Enhancing Expression of Functional Human Sodium Iodide Symporter and Somatostatin Receptor in Recombinant Oncolytic Vaccinia Virus for In Vivo Imaging of Tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Vaccinia virus GLV-1h153 in combination with 131I shows increased efficiency in treating triple-negative breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Assessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2018.04.001

Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase

7 January 2021

1 reference

12 December 2020

A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer

1 reference

12 December 2020

Targeting Tumors with Salmonella Typhimurium - Potential for Therapy

1 reference

12 December 2020

Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells

1 reference

12 December 2020

Combination of fractionated irradiation with anti-VEGF expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium

1 reference

12 December 2020

Synergy of cancer immunotherapy and radiotherapy

1 reference

12 December 2020

Therapeutic potential of oncolytic Newcastle disease virus: a critical review

1 reference

12 December 2020

Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances

1 reference

12 December 2020

The efficacy of combination therapy with oncolytic herpes simplex virus HF10 and dacarbazine in a mouse melanoma model

1 reference

12 December 2020

Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells

1 reference

12 December 2020